[The effect of the different immunosuppression therapy on CD4(+)Foxp3(+) Treg cells in kidney recipients].
OBJECTIVE
To investigate the effect of the different immunosuppression therapy on CD4(+)Foxp3(+)regulatory T cells (CD4(+)Foxp3(+)Treg cells) in the peripheral blood monocytes of kidney transplantation recipients.


METHODS
A Closed Cohort study was conducted in 50 primary living kidney transplant recipients between January 2006 and January 2008, who had been followed up for 1 year. The recipients divided into calcineurin inhibitors group (CNI + MMF + Pred) (19 recipients, including cyclosporin group 10 recipients and tacrolimus group 9 recipients), rapamycin group (RAPA + MMF + Pred) (31 recipients). Twenty end-stage renal disease patients were in control group. The frequency of CD4(+)Foxp3(+)Treg cells in total CD4(+)T cells was analyzed by flow cytometry in peripheral blood from three groups, results were compared.


RESULTS
The clinical variables of recipients such as age, sex, cold ischemia time, human leucocyte antigen mismatch, panel reaction antibody, rejection episode were no significant difference. The percentage of CD4(+)Foxp3(+)Treg cells in total CD4(+) cells was significantly higher in rapamycin group and end-stage renal disease group than calcineurin inhibitors group (P < 0.01). The level of CD4(+)Foxp3(+)Treg cells between cyclosporin group and tacrolimus group was no significant difference (P > 0.05).


CONCLUSIONS
The level of CD4(+)Foxp3(+)Treg was significantly higher in patients receiving RAPA + MMF + Pred than the patients receiving CNI + MMF + Pred, which suggested that RAPA may be play a more important role in immune tolerance induction.
Mo
Chun-bai
CB
Department of Transplantation, Tianjin First Center Hospital, Tianjin 300192, China. Email: cbmo@medmail.com.cn.
Song
Wen-li
WL
Wang
Zhi-ping
ZP
Zheng
Jian-ming
JM
Fu
Ying-xin
YX
Feng
Gang
G
Pei
Guang-hui
GH
Zhao
Jie
J
Shi
Xiao-feng
XF
Liu
Hang
H
D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D051858:Forkhead Transcription Factors; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology*
D051858:Forkhead Transcription Factors; D007166:Immunosuppressive Agents; D020123:Sirolimus